 Exons
"Exons" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The parts of a transcript of a split GENE remaining after the INTRONS are removed. They are spliced together to become a MESSENGER RNA or other functional RNA.
| Descriptor ID |
D005091
|
| MeSH Number(s) |
G05.360.340.024.340.137.232
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Exons".
Below are MeSH descriptors whose meaning is more specific than "Exons".
This graph shows the total number of publications written about "Exons" by people in this website by year, and whether "Exons" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1987 | 0 | 1 | 1 | | 1988 | 0 | 1 | 1 | | 1989 | 0 | 4 | 4 | | 1990 | 1 | 2 | 3 | | 1991 | 1 | 7 | 8 | | 1992 | 0 | 10 | 10 | | 1993 | 1 | 8 | 9 | | 1994 | 0 | 10 | 10 | | 1995 | 3 | 6 | 9 | | 1996 | 1 | 14 | 15 | | 1997 | 3 | 10 | 13 | | 1998 | 1 | 11 | 12 | | 1999 | 2 | 13 | 15 | | 2000 | 1 | 17 | 18 | | 2001 | 2 | 8 | 10 | | 2002 | 3 | 15 | 18 | | 2003 | 2 | 18 | 20 | | 2004 | 2 | 10 | 12 | | 2005 | 2 | 11 | 13 | | 2006 | 3 | 6 | 9 | | 2007 | 0 | 12 | 12 | | 2008 | 0 | 9 | 9 | | 2009 | 0 | 13 | 13 | | 2010 | 3 | 12 | 15 | | 2011 | 2 | 14 | 16 | | 2012 | 3 | 11 | 14 | | 2013 | 1 | 4 | 5 | | 2014 | 0 | 8 | 8 | | 2015 | 3 | 7 | 10 | | 2016 | 4 | 6 | 10 | | 2017 | 2 | 5 | 7 | | 2018 | 2 | 4 | 6 | | 2019 | 3 | 2 | 5 | | 2020 | 2 | 2 | 4 | | 2021 | 1 | 4 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Exons" by people in Profiles.
-
Zhang X, Zhang CM, Prokopenko D, Liang Y, Zhen SY, Weigle IQ, Han W, Aryal M, Tanzi RE, Sisodia SS. An APP ectodomain mutation outside of the Aß domain promotes Aß production in vitro and deposition in vivo. J Exp Med. 2021 06 07; 218(6).
-
Kohli U, Sriram CS, Nayak HM. A novel familial SCN5A exon 20 deletion is associated with a heterogeneous phenotype. J Electrocardiol. 2021 May-Jun; 66:131-135.
-
Prelaj A, Bottiglieri A, Proto C, Lo Russo G, Signorelli D, Ferrara R, Galli G, De Toma A, Viscardi G, Brambilla M, Lobefaro R, Nichetti F, Manglaviti S, Occhipinti M, Labianca A, Ganzinelli M, Gallucci R, Zilembo N, Greco GF, Torri V, de Braud F, Garassino MC. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. Eur J Cancer. 2021 05; 149:235-248.
-
Lapadat R, Anani WQ, Bensing KM, Aeschlimann J, Vege S, Lomas-Francis C, Westhoff CM, Fadeyi EA, Denomme GA. A pair of S-silencing single nucleotide variants cis-linked on GYPB. Transfusion. 2021 04; 61(4):E34-E36.
-
Strittmatter LM, Capitanchik C, Newman AJ, Hallegger M, Norman CM, Fica SM, Oubridge C, Luscombe NM, Ule J, Nagai K. psiCLIP reveals dynamic RNA binding by DEAH-box helicases before and after exon ligation. Nat Commun. 2021 03 05; 12(1):1488.
-
Roth KG, Mambetsariev I, Salgia R. Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report. Cold Spring Harb Mol Case Stud. 2020 12; 6(6).
-
Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 09 03; 383(10):931-943.
-
Schoch K, Tan QK, Stong N, Deak KL, McConkie-Rosell A, McDonald MT. Alternative transcripts in variant interpretation: the potential for missed diagnoses and misdiagnoses. Genet Med. 2020 07; 22(7):1269-1275.
-
Salgia R, Sattler M, Scheele J, Stroh C, Felip E. The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treat Rev. 2020 Jul; 87:102022.
-
Demonbreun AR, Wyatt EJ, Fallon KS, Oosterbaan CC, Page PG, Hadhazy M, Quattrocelli M, Barefield DY, McNally EM. A gene-edited mouse model of limb-girdle muscular dystrophy 2C for testing exon skipping. Dis Model Mech. 2019 11 04; 13(2).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|